Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
LONDON, June 10, 2016 /PRNewswire/ --
Companies Looking to Replicate Wet AMD Drug Successes in Dry AMD, Glaucoma and Allergic, Inflammatory & Infective Ocular Conditions
What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.
Our 220-page report provides 160 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.
In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs
To see a report overview please email Sara Peerun on [email protected]
The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju
• Akorn
The report also includes revenue forecasts to 2026 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Restasis
• Lumigan and Ganfort
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Vigamox
• Xalatan/Xalacom
• Azopt
• Jetrea
• Hyalein
• Cosopt
• Tapros/Taflotan
• Diquas
• Cravit
• Alesion
• Lotemax
Leading companies and potential for market growth
Novartis (including subsidiary Alcon) will remain the leading ophthalmic company to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.
Our work analyses the key companies in the market. See visiongain's analysis of over 25 leading companies, including these:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju
• Akorn
A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Revenue forecasts to 2016 for ophthalmic drugs marketed by the company
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the ophthalmic drugs industry?
Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026report helps you
In summary, our 220-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the 10 leading companies in the market - discover the industry's prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju and Akorn
• Revenue forecasts to 2026 for each major submarket - discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.
• Revenue forecasts to 2026 for 17 leading drugs - discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Restasis, Lumigan and Ganfort, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Vigamox, Xalatan/Xalacom, Azopt, Jetrea, Hyalein, Cosopt, Tapros/Taflotan, Diquas, Cravit, Alesion and Lotemax.
• Assessment of 21 emerging ophthalmic companies - analysis of products, revenue, mergers & acquisitions and leading pipeline drug candidates
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
To see a report overview please email Sara Peerun on [email protected]
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100 Or click on https://www.visiongain.com/Report/1654/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2016-2026
Companies mentioned
Actavis
Acucela
Advanced Vision Research
Aerie Pharmaceuticals
Aerpio Therapeutics, Inc
Alcon
Akorn
Algeta
Alimera Sciences
Allergan
Allegro Ophthalmics
Amakem
Ampio Pharmaceuticals
Asahi Glass
Aton Pharma, Inc.
Aventis
AYUMI Pharmaceutical Corporation
Banyu Pharmaceutical
Barr Laboratories
Bausch & Lomb
Bayer AG
Bayer HealthCare
Bayer Yakuhin
Bristol-Myers Squibb
Can-Fite BioPharma
Chiron Corporation
Chugai Pharmaceutical
Ciba-Geigy
Ciba Vision
Chengdu Kanghong Pharmaceutical
Eleven Biotherapeutics
Eli Lilly
EyeGate Pharmaceuticals
Eyetech Inc.
Fougera Pharmaceuticals
Genentech
Gene Signal
GSK
Hi-Tech
Hospira Inc
ICN Pharmaceuticals
Icon Bioscience
Inception Sciences, Inc.
InSite Vision
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Jenapharm
Kestrel Ophthalmics
King Pharmaceuticals
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
MacuCLEAR
MacuSight, Inc.
MAP Pharmaceuticals
MEAgate International FZLLC
Meda
Medicis Corporation
Merck & Co.
MerLion
MSD K.K.
Mystic Pharmaceuticals
Nestlé
Neurotech
Nippon Boehringer Ingelheim Co.,Ltd.
NovaBay Pharmaceuticals
Novagali Pharma
Novartis International AG
Novartis Institutes for BioMedical Research
Novartis Venture Funds
OcuSciences
Omeros
OphthtaliX
Ophthotech
Ora, Inc.
Otsuka Pharmaceutical
Parke-Davis
Par Pharmaceutical
Pfizer Inc.
Pharmacia
Philidor
PreCision Dermatology
Premacure
Procter & Gamble
pSivida Corp.
Quark Pharmaceuticals
Regeneron
Rekitt Benckiser
Roche Consumer Health
RXi Pharmaceuticals
Salix
Sandoz
Sanofi
Sanofi-Aventis
Santaris Pharma
Santen Pharmaceutical Co.
Santen S.A.S.
SARcode Bioscience
Schering AG
Senju Pharmaceutical Company Ltd.
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd.
Senju USA Inc.
Shire
SkinMedica
Spark Therapeutics
Steigerwald
ThromboGenics
Upjohn
Valeant Pharmaceuticals International Ventana Medical Systems
Versant Ventures
VersaPharm
Warburg Pincus LLC
Warner-Lambert
Wyeth Pharmaceuticals
Zoetis
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article